The dulaglutide data were revealed today at the annual American Diabetes Association meeting. Dulaglutide could restore some pride in Lilly's much-maligned R&D engine.

对于 2 型糖尿病（T2D）血糖控制不佳的患者，提升 Dulaglutide（胰高血糖素样肽 - 1 受体激动剂，GLP - 1）剂量不如换用 Tirzepatide。研究发现，换用并加量 Tirzepatide 者 40 周后 21% 的人糖化血红蛋白 A1c（HbA1c）达标，且减重效果更好，安全性相似。此研究为 T2D 治疗提供新方向。

2020年09月27日讯 / 生物谷 BIOON/ -- 礼来 （Eli Lilly）近日宣布，加拿大卫生部（Health Canada）已批准降糖药Trulicity（dulaglutide，度拉鲁肽），该药是一种 ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

传统肽类药物如dulaglutide需每周给药，且生产工艺复杂。 面对这些瓶颈，中国某研究机构团队在《Journal of Pharmaceutical Sciences》发表研究，创新性地将mRNA技术与Fc融合蛋白策略结合，开发出能持续表达GLP-1-Fc的mRNA药物。

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to ...